Policlinica De Diagnostic Rapid S.A.
- Address
- lock Available on a paid plan
Oncology Research
At Policlinica De Diagnostic Rapid S.A. in Brașov, the Oncologie medicala department is involved in clinical studies focused on neoplasms, especially prostate cancer and cancers with specific genetic features such as HRRm or HRD. These trials are designed to assess how well new cancer treatments work and to better understand treatment benefit in patients with difficult-to-treat disease.
- Testing targeted therapy options for HRRm or HRD-positive cancer
- Evaluating treatment effectiveness in castration-resistant prostate cancer
- Studying ways to improve outcomes for men with advanced prostate disease
The oncology portfolio reflects a strong interest in precision medicine and in measuring meaningful responses to treatment in patients with advanced malignancies.
Respiratory Disease Research
The site also supports trials in respiratory tract diseases, with a major focus on asthma in adults and adolescents. Research here includes eosinophilic asthma, severe eosinophilic asthma, and severe inadequately controlled asthma, aiming to improve symptom control, lung function, and day-to-day disease management.
- Assessing new inhaled treatments for severe asthma
- Improving control in eosinophilic asthma
- Studying options for patients with inadequately controlled asthma
These studies are intended to help identify therapies that can reduce flare-ups and support better breathing outcomes in people whose asthma remains difficult to manage.
Advanced Therapy Evaluation
Several trials at this Romanian research site are centered on evaluating newer medicines for both oncology and asthma. The work includes testing targeted cancer treatments as well as therapies aimed at reducing inflammation and improving respiratory function, showing a broad commitment to clinically meaningful treatment advances.
- Evaluating targeted treatment benefit in prostate cancer
- Testing whether new asthma therapies can reduce exacerbations
- Assessing improvements in lung function and symptom control
Overall, the research activity combines cancer care and respiratory medicine with a focus on practical outcomes that matter to patients and clinicians.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Areteia Therapeutics Inc.3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Policlinica De Diagnostic Rapid S.A.
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer | Merck Sharp & Dohme LLC | Phase II | Not Recruiting | Dec 2018 | Dec 2025 |
IMP list
lock Showing 1 of 13 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexpramipexole Dihydrochloride Monohydrate | 3 | Unknown | 2023-04-25 | 2024-10-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.